On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer

European Journal of Cancer

Volumn 46, Issue 17, 2010, Pages 3109-3119

  Bangma, Chris H ^a   Van Schaik, Ron H ^a   Blijenberg, Bert G ^a   Roobol, Monique J ^a   Lilja, Hans ^b   Stenman, Ulf Hkan ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Prostate cancer; PSA; Review; Screening; Tumour marker

Indexed keywords

KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 2; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; URINALYSIS;

EID: 78049457613     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.09.031     Document Type: Article

References (102)

1. G. De Angelis, H.G. Rittenhouse, S.D. Mikolajczyk, L. Blair Shamel, and A. Semjonow Twenty years of PSA: from prostate antigen to tumor marker Rev Urol 9 3 2007 113 123
2. J. Hernandez, and I.M. Thompson Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker Cancer 101 5 2004 894 904
3. W.J. Catalona, D.S. Smith, and T.L. Ratliff Measurement of prostate-specific antigen in serum as a screening test for prostate cancer New Engl J Med 324 17 1991 1156 1161
4. P.M. Beemsterboer, H.J. de Koning, and R. Kranse Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam J Urol 164 4 2000 1216 1220
5. P. Lodding, G. Aus, and S. Bergdahl Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml prostate specific antigen J Urol 159 3 1998 899 903
6. H. Lilja, D. Ulmert, and A.J. Vickers Prostate-specific antigen and prostate cancer: prediction, detection and monitoring Nat Rev Cancer 8 4 2008 268 278
7. J.L. Bosch, K. Tilling, A.M. Bohnen, and J.L. Donovan Establishing normal reference ranges for PSA change with age in a population-based study: The Krimpen study Prostate 66 4 2006 335 343
8. I.M. Thompson, D.K. Pauler, and P.J. Goodman Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng/ml New Engl J Med 350 22 2004 2239 2246
9. B.G. Blijenberg, H. Lilja, H. Neels, and U.H. Stenman Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA committee BJU Int 92 Suppl 2 2003 66 70
10. R. Raaijmakers, M.F. Wildhagen, and K. Ito Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam Urology 63 2 2004 316 320
11. A.J. Vickers, A.M. Cronin, and M.J. Roobol The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group Clin Cancer Res 16 17 2010 4374 4381
12. A.J. Vickers, A.M. Cronin, and G. Aus Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden Cancer 116 11 2010 2612 2620
13. D. Ulmert, A.M. Cronin, and T. Bjork BMC Med 6 2008 6
14. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 4 2009 225 249
15. O. Fadare, S. Wang, and M.R. Mariappan Practice patterns of clinicians following isolated diagnoses of atypical small acinar proliferation on prostate biopsy specimens Arch Pathol Lab Med 128 5 2004 557 560
16. G. Draisma, R. Boer, and S.J. Otto Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 12 2003 868 878
17. U. Stenman, P. Finne, W. Zhang, and J. Leinonen Prostate-specific antigen and other prostate cancer markers Urology 56 6 2000 893 898
18. A.R. Rao, H.G. Motiwala, and O.M. Karim The discovery of prostate-specific antigen BJU Int 101 1 2008 5 10
19. M.C. Wang, L.A. Valenzuela, G.P. Murphy, and T.M. Chu Purification of a human prostate specific antigen Invest Urol 17 2 1979 159 163
20. T.A. Stamey, N. Yang, and A.R. Hay Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate New Engl J Med 317 15 1987 909 916
21. H. Lilja A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein J Clin Invest 76 5 1985 1899 1903
22. A. Lundwall, and H. Lilja Molecular cloning of human prostate specific antigen cDNA FEBS Lett 214 2 1987 317 322
23. A. Christensson, C.B. Laurell, and H. Lilja Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors Eur J Biochem 194 3 1990 755 763
24. H. Lilja, A. Christensson, and U. Dahlen Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin Clin Chem 37 9 1991 1618 1625
25. U.H. Stenman, J. Leinonen, and H. Alfthan A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer Cancer Res 51 1 1991 222 226
26. Stamey TA, Ekman PE, Blankenstein MA, et al. Tumor markers. Consensus conference on diagnosis and prognostic parameters in localized prostate cancer, Stockholm, Sweden, May 12-13, 1993. Scand J Urol Nephrol Suppl 1994;162:73-87 [discussion 115-27].
27. B. Rafferty, P. Rigsby, M. Rose, T. Stamey, and R. Gaines Das Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10) Clin Chem 46 9 2000 1310 1317
28. T. Piironen, B.O. Villoutreix, and C. Becker Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling Protein Sci 7 2 1998 259 269
29. M.J. Bussemakers, A. van Bokhoven, and G.W. Verhaegh DD3: a new prostate-specific gene, highly overexpressed in prostate cancer Cancer Res 59 23 1999 5975 5979
30. B.G. Blijenberg, G. Yurdakul, and B.D. Van Zelst Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer BJU Int 88 6 2001 545 550
31. Graves HC. Standardization of immunoassays for prostate-specific antigen. A problem of prostate-specific antigen complexation or a problem of assay design? Cancer 1993;72(11):3141-4.
32. L.J. Denis, G.P. Murphy, and F.H. Schroder Report of the consensus workshop on screening and global strategy for prostate cancer Cancer 75 5 1995 1187 1207
33. R.J. Laffin, D.W. Chan, and M.J. Tanasijevic Hybritech total and free prostate-specific antigen assays developed for the Beckman Coulter access automated chemiluminescent immunoassay system: a multicenter evaluation of analytical performance Clin Chem 47 1 2001 129 132
34. C. Stephan, C. Bangma, G. Vignati, G. Bartsch, M. Lein, and K. Jung 20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials - analysis of 1098 patients in four centers Int J Biol Markers 24 2 2009 65 69
35. F.H. Jansen, M. Roobol, C.H. Bangma, and R.H. van Schaik Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection Clin Chem 54 12 2008 1999 2006
36. A. Christensson, T. Bjork, and O. Nilsson Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer J Urol 150 1 1993 100 105
37. M.K. Brawer, C.D. Cheli, and I.E. Neaman Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer J Urol 163 5 2000 1476 1480
38. W.J. Catalona, A.W. Partin, and K.M. Slawin Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial Jama 279 19 1998 1542 1547
39. J.B. Rietbergen, A.E. Kruger, and R.F. Hoedemaeker Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer J Urol 160 6 Pt 1 1998 2121 2125
40. J. Hugosson, G. Aus, and S. Bergdahl Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden BJU Int 92 Suppl 2 2003 39 43
41. P.C. Prorok, G.L. Andriole, and R.S. Bresalier Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial Control Clin Trials 21 6 Suppl 2000 273S 309S
42. W.J. Catalona, J.P. Richie, and F.R. Ahmann Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men J Urol 151 5 1994 1283 1290
43. M.J. Roobol, R. Kranse, H.J. de Koning, and F.H. Schroder Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM) Urology 63 2 2004 309 313 [discussion 313-5]
44. F. Recker, M.K. Kwiatkowski, and A. Huber Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng/ml combined with free-to-total ratio 20% or less: the Aarau experience J Urol 166 3 2001 851 855
45. P. Finne, A. Auvinen, and L. Maattanen Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 mg/l Eur Urol 54 2 2008 362 370
46. R. Raaijmakers, B.G. Blijenberg, and J.A. Finlay Prostate cancer detection in the prostate specific antigen range of 2 0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol 171 6 Pt 1 2004 2245 2249
47. P. Finne, R. Finne, and A. Auvinen Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network Urology 56 3 2000 418 422
48. P. Finne, R. Finne, and C. Bangma Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening Int J Cancer 111 2 2004 310 315
49. C.H. Bangma, R. Kranse, B.G. Blijenberg, and F.H. Schroder The value of screening tests in the detection of prostate cancer. Part I: results of a retrospective evaluation of 1726 men Urology 46 6 1995 773 778
50. C.H. Bangma, J.B. Rietbergen, and R. Kranse The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population J Urol 157 6 1997 2191 2196
51. Becker C, Piironen T, Pettersson K, Hugosson J, Lilja H. Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer. J Urol 2003;170(4 Pt 1):1169-74.
52. A.J. Vickers, A.M. Cronin, and G. Aus BMC Med 6 2008 19
53. J.B. Rietbergen, R. Kranse, and R.F. Hoedemaeker Comparison of prostate-specific antigen corrected for total prostate volume and transition zone volume in a population-based screening study Urology 52 2 1998 237 246
54. C.H. Bangma, J.B. Rietbergen, and F.H. Schroder Prostate-specific antigen as a screening test. The Netherlands experience Urol Clin North Am 24 2 1997 307 314
55. F.H. Schroder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study New Engl J Med 360 13 2009 1320 1328
56. T. Wolters, M.J. Roobol, C.H. Bangma, and F.H. Schroder Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam) Eur Urol 55 2 2009 385 392
57. Vickers AJ, Wolters T, Savage CJ, et al. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based Cohort. Eur Urol 2009.
58. C. Gosselaar, M.J. Roobol, R.C. van den Bergh, T. Wolters, and F.H. Schroder Digital rectal examination and the diagnosis of prostate cancer - a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam Eur Urol 55 1 2009 139 146
59. F.H. Schroder, P. van der Maas, and P. Beemsterboer Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 90 23 1998 1817 1823
60. H. Lilja, D. Ulmert, and T. Bjork Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years J Clin Oncol 25 4 2007 431 436
61. M.F. Darson, A. Pacelli, and P. Roche Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker Urology 49 6 1997 857 862
62. H.G. Rittenhouse, J.A. Finlay, S.D. Mikolajczyk, and A.W. Partin Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate Crit Rev Clin Lab Sci 35 4 1998 275 368
63. C. Becker, T. Piironen, K. Pettersson, J. Hugosson, and H. Lilja Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater Urology 55 5 2000 694 699
64. M.F. Darson, A. Pacelli, and P. Roche Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases Urology 53 5 1999 939 944
65. J. Lovgren, K. Rajakoski, M. Karp, A. Lundwall, and H. Lilja Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2 Biochem Biophys Res Commun 238 2 1997 549 555
66. T.K. Takayama, K. Fujikawa, and E.W. Davie Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein J Biol Chem 272 34 1997 21582 21588
67. J. Lovgren, T. Piironen, and C. Overmo Production of recombinant PSA and HK2 and analysis of their immunologic cross-reactivity Biochem Biophys Res Commun 213 3 1995 888 895
68. T. Piironen, J. Lovgren, and M. Karp Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum Clin Chem 42 7 1996 1034 1041
69. A. Haese, V. Vaisanen, and J.A. Finlay Standardization of two immunoassays for human glandular kallikrein 2 Clin Chem 49 4 2003 601 610
70. R. Raaijmakers, S.H. de Vries, and B.G. Blijenberg HK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml Eur Urol 52 5 2007 1358 1364
71. A. Haese, M. Graefen, and T. Steuber Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml Prostate 49 2 2001 101 109
72. F. Recker, M.K. Kwiatkowski, and T. Piironen Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen Urology 55 4 2000 481 485
73. S.D. Mikolajczyk, L.S. Marks, A.W. Partin, and H.G. Rittenhouse Free prostate-specific antigen in serum is becoming more complex Urology 59 6 2002 797 802
74. 146 inactive PSA Clin Chem 46 10 2000 1610 1618
75. K.W. Watt, P.J. Lee, T. M'Timkulu, W.P. Chan, and R. Loor Human prostate-specific antigen: structural and functional similarity with serine proteases Proc Natl Acad Sci USA 83 10 1986 3166 3170
76. S.D. Mikolajczyk, L.S. Millar, and T.J. Wang "BPSA", a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia Urology 55 1 2000 41 45
77. 146 Clin Chem 47 8 2001 1415 1423
78. V. Vaisanen, M.T. Peltola, H. Lilja, M. Nurmi, and K. Pettersson Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab′)2 fragments Anal Chem 78 22 2006 7809 7815
79. S.D. Mikolajczyk, K.M. Marker, and L.S. Millar A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer Cancer Res 61 18 2001 6958 6963
80. T. Steuber, P. Niemela, and A. Haese Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue Prostate 63 1 2005 13 18
81. S.H. de Vries, R. Raaijmakers, and B.G. Blijenberg Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer Urology 65 5 2005 926 930
82. H.J. Linton, L.S. Marks, and L.S. Millar Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease Clin Chem 49 2 2003 253 259
83. Canto EI, Singh H, Shariat SF, et al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 2004;63(5):905-10 [discussion 910-1].
84. Jansen FH, van Schaik RH, Kurstjens J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010 [Epub ahead of print].
85. F.H. Jansen, M. Roobol, G. Jenster, F.H. Schroder, and C.H. Bangma Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins Eur Urol 55 3 2009 563 574
86. K. Mitrunen, K. Pettersson, and T. Piironen Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum Clin Chem 41 8 Pt 1 1995 1115 1120
87. A.J. Vickers, A.M. Cronin, and M.J. Roobol A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam Clin Cancer Res 16 12 2010 3232 3239
88. M.J. Roobol, E.W. Steyerberg, and R. Kranse A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer Eur Urol 57 1 2010 79 85
89. G. Yurdakul, C.H. Bangma, and B.G. Blijenberg Different PSA assays lead to detection of prostate cancers with identical histological features Eur Urol 42 2 2002 154 158
90. E.W. Steyerberg, M.J. Roobol, and M.W. Kattan Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram J Urol 177 1 2007 107 112 [discussion 112]
91. M.R. Cooperberg, D.P. Lubeck, S.S. Mehta, and P.R. Carroll CaPSURE: time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE) J Urol 170 6 Pt 2 2003 S21 S25 [discussion S26-7]
92. M.P. van Gils, U.H. Stenman, and J.A. Schalken Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project Eur Urol 48 6 2005 1031 1041
93. G.J. van den Bemd, J. Krijgsveld, and T.M. Luider Mass spectrometric identification of human prostate cancer-derived proteins in serum of xenograft-bearing mice Mol Cell Proteomics 5 10 2006 1830 1839
94. U.H. Stenman, P.A. Abrahamsson, and G. Aus Prognostic value of serum markers for prostate cancer Scand J Urol Nephrol Suppl 216 2005 64 81
95. A. Auvinen, L. Maattanen, and P. Finne Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial Int J Cancer 111 6 2004 940 943
96. P. Finne, A. Auvinen, and H. Koistinen Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen J Clin Endocrinol Metab 85 8 2000 2744 2747
97. J.A. Janssen, M.F. Wildhagen, and K. Ito Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval J Clin Endocrinol Metab 89 9 2004 4391 4396
98. L. Llanes, A. Paez, and A. Ferruelo Detecting circulating prostate cells in patients with clinically localized prostate cancer: clinical implications for molecular staging BJU Int 86 9 2000 1023 1027
99. van Leeuwen PJ, Connolly D, Tammela TL, et al. Balancing the harms and benefits of early detection of prostate cancer. Cancer 2010 [Epub ahead of print].
100. A.J. Vickers, D. Ulmert, and A.M. Serio The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy Int J Cancer 121 10 2007 2212 2217
101. H. Passing, and W. Bablok A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, part I J Clin Chem Clin Biochem 21 11 1983 709 720
102. J.M. Bland, and D.G. Altman Statistical methods for assessing agreement between two methods of clinical measurement Lancet 1 8476 1986 307 310